Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ELI LILLY AND COMPANY

(LLY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

GenEdit Inc announced that it has received $26 million in funding from a group of investors

09/23/2021 EDT

GenEdit Inc announced that it has received $26,000,000 in a round of funding on September 23, 2021. The transaction included participation from new investors, Eli Lilly and Company, KTB Network Co., Ltd., Company K Partners Limited, Korea Investment Partners Co. Ltd., DAYLI Partners Co., Ltd., KB Investment Co., Ltd., IMM Investment Corp., Timefolio Asset Management Co.,Ltd, returning investors, DCVC Bio, L.P., a fund managed by Data Collective, SK Holdings Co, Ltd., Investment Arm, Bow Capital and Sequoia Capital Operations LLC.


ę S&P Capital IQ 2021
All news about ELI LILLY AND COMPANY
10/14ELI LILLY AND : Releases Updated Data From Phase 3 Breast Cancer Trial
MT
10/14ELI LILLY AND : Lilly Announces Updated Verzenio« (abemaciclib) Phase 3 monarchE Trial Dat..
PR
10/14Eli Lilly and Company Announces Updated Verzenio« (abemaciclib) Phase 3 monarchE Trial ..
CI
10/13AGILENT TECHNOLOGIES : Eli Lilly Get FDA's OK for Assay to Identify Early Breast Cancer
MT
10/13ELI LILLY AND : Combination Therapy Receives FDA Approval as Adjuvant Treatment for Certai..
MT
10/13ELI LILLY AND : FDA Approves Verzenio« (abemaciclib) as the First and Only CDK4/6 Inhibito..
PR
10/13FDA Approves Verzenio« (abemaciclib) as the First and Only CDK4/6 Inhibitor for Certain..
CI
10/13ELI LILLY : FDA Approves Verzenio in Some High-Risk Early Breast-Cancer Patients
DJ
10/13Hemogenyx Pharmaceuticals plc Announces CDX Licence Agreement
CI
10/13Hemogenyx Signs Licensing Agreement With Eli Lilly for Antibody
DJ
More news
Analyst Recommendations on ELI LILLY AND COMPANY
More recommendations
Financials (USD)
Sales 2021 27 353 M - -
Net income 2021 6 481 M - -
Net Debt 2021 11 548 M - -
P/E ratio 2021 33,3x
Yield 2021 1,38%
Capitalization 216 B 216 B -
EV / Sales 2021 8,31x
EV / Sales 2022 8,05x
Nbr of Employees 35 000
Free-Float 99,8%
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | LLY | US5324571083 | MarketScreener
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 19
Last Close Price 237,88 $
Average target price 269,42 $
Spread / Average Target 13,3%
EPS Revisions
Managers and Directors
David A. Ricks Chairman, President & Chief Executive Officer
Anat Ashkenazi Chief Financial Officer & Senior Vice President
Timothy J. Garnett Chief Medical Officer & VP-Global Medical
Daniel M. Skovronsky Chief Scientific Officer & Senior Vice President
Diogo Rau Senior VP, Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
ELI LILLY AND COMPANY40.89%215 657
JOHNSON & JOHNSON2.49%424 619
ROCHE HOLDING AG16.59%339 442
NOVO NORDISK A/S54.22%234 792
PFIZER, INC.13.20%232 621
MERCK & CO., INC.-4.24%198 283